Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Receivables: 2019-2024

Historic Receivables for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $3.1 million.

  • C4 Therapeutics' Receivables fell 36.74% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.8 million, marking a year-over-year decrease of 46.27%. This contributed to the annual value of $3.1 million for FY2024, which is 73.71% down from last year.
  • Per C4 Therapeutics' latest filing, its Receivables stood at $3.1 million for FY2024, which was down 73.71% from $11.8 million recorded in FY2023.
  • C4 Therapeutics' 5-year Receivables high stood at $11.8 million for FY2023, and its period low was $1.5 million during FY2022.
  • Its 3-year average for Receivables is $5.5 million, with a median of $3.1 million in 2024.
  • As far as peak fluctuations go, C4 Therapeutics' Receivables tumbled by 74.23% in 2022, and later spiked by 701.02% in 2023.
  • Over the past 5 years, C4 Therapeutics' Receivables (Yearly) stood at $4.5 million in 2020, then grew by 27.48% to $5.7 million in 2021, then tumbled by 74.23% to $1.5 million in 2022, then soared by 701.02% to $11.8 million in 2023, then tumbled by 73.71% to $3.1 million in 2024.